Point of Care Testing - for Inflammatory Bowel Disease - Capable of distinguishing between Ulcerative Colitisand Crohn’s Disease
The Invention
Inflammatory bowel disease is a life-long relapsing and remitting inflammatory disorder primarily affecting the gastrointestinal tract.
Invasive diagnostic investigations, specifically colonoscopy and histopathological evaluation, are the current standard for diagnosis.
This invention provides a method ofdiagnosing or assessing inflammatory bowel disease including Crohn’s disease and Ulcerative Colitis using a set of six protein/peptide markers by comparing the level of one or more markers relative to a reference value for the one or more markers.
The technology is also capable of distinguishing between Ulcerative Colitis and Crohn’s disease and the severity of the condition.
Key Benefits
The development of a point of care diagnostic test would provide:
· Non-invasive testing
· Rapid test and results
· Accurate diagnosis
· Significant reduction in medical costs
· Faster intervention - better treatment options
· Better disease management
The Opportunity
UNSW is seeking a commercial partner to licence and/or to work collaboratively with the inventorDr Valerie Wasinger in the development of this diagnostic test.
https://research.unsw.edu.au/people/dr-valerie-wasinger/publications
Click here for a Print version of this technoloy brief
For more information contact:
Dr Joe Brennan
Business Development Manager
NewSouth Innovations
Ref: 13_2780
T: +61 2 9385 7729 l M: +61 450 469 492
E: j.brennan@nsinnovations.com.au